title: Anti-angiogenic properties of plaunotol.
abstract: We have investigated a potential anti-angiogenic effect of plaunotol, an extract from the leaves of Plau-noi, in an angiogenesis model consisting of human umbilical vein endothelial cells (HUVECs). Plaunotol inhibited the proliferative activity of HUVECs in a dose-dependent manner. In addition, it caused a remarkable decrease of the ability of HUVECs to adhere and spread on gelatin and vitronectin, but not fibronectin. Tube-like formation in Matrigel was also inhibited in a dose-dependent way. These results strongly suggest the specific inhibition of integrin alphavbeta3 to be the main event of plaunotol-induced suppression of angiogenesis. The alphavbeta3 antagonists are known to be potent inhibitors of tumor angiogenesis and plaunotol, by causing the functional inhibition of alphavbeta3, should be considered a promising new anti-angiogenic drug.
authors.affiliation: Department of Surgical Oncology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. kz-kawai@mvd.biglobe.ne.jp
authors.forename: Kazushige
authors.initials: K
authors.lastname: Kawai
authors.forename: Nelson H
authors.initials: NH
authors.lastname: Tsuno
authors.forename: Joji
authors.initials: J
authors.lastname: Kitayama
authors.forename: Yurai
authors.initials: Y
authors.lastname: Okaji
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yazawa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asakage
authors.forename: Hiroharu
authors.initials: H
authors.lastname: Yamashita
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Watanabe
authors.forename: Koki
authors.initials: K
authors.lastname: Takahashi
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Nagawa
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D003094:Collagen / Q000378:metabolism; D004224:Diterpenes; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D042783:Endothelial Cells / Q000187:drug effects*; D005233:Fatty Alcohols / Q000494:pharmacology*; D005353:Fibronectins / Q000378:metabolism; D005780:Gelatin / Q000378:metabolism; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D007797:Laminin / Q000378:metabolism; D011509:Proteoglycans / Q000378:metabolism; D014471:Umbilical Veins / Q000166:cytology; D019096:Vitronectin / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D004224:Diterpenes; D004338:Drug Combinations; D005233:Fatty Alcohols; D005353:Fibronectins; D039302:Integrin alphaVbeta3; D007797:Laminin; D011509:Proteoglycans; D019096:Vitronectin; C059485:matrigel; D005780:Gelatin; D003094:Collagen; C047686:plaunotol